Neuroimaging in Parkinson Disease by Mohammad, Roohi & Mubarak, Fatima
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Neuroimaging in Parkinson 
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Abstract
Over many decades, neuroimaging which included structural, functional and 
molecular modalities—have provided invaluable insights into the mechanisms 
underlying Parkinson disease (PD). These studies have shown changes in brain 
structure and metabolic activity. Although it is now considered to be complex, still 
neuroimaging modalities are recommended for routine use in clinical practice. 
Special sequences such as susceptibility weighted and proton density sequences are 
recommended for characterization. Now, the world is switching more towards the 
deep brain stimulation so the neuroimaging also helps in pretreatment planning and 
post treatment complications assessments. This chapter discusses the radiological 
anatomy, sequencing and imaging appearances. It will also discuss new approaches 
with potential applicability to clinical practice.
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1. Introduction
Parkinson’s disease (PD) is a communal neurodegenerative disorder with a 
prevalence of 160/100,000 in Western Europe rising to 4% of the population over 
80 [1]. With an increase in average age, the management of PD is increasingly 
imperative and perplexing aspect of medical practice for the neurologists and 
general physicians. The pathogenesis of the disease has been advanced in the last 
decade with the identification of several gene mutations and the mechanisms of 
pathogenesis in sporadic cases of PD. The diagnosis of PD remains fundamen-
tally a clinical, and it is significant to recognize the early features together with 
symptoms and signs suggesting other causes of Parkinsonism. There has also been 
a rapid expansion in the management options together with a greater awareness 
of non-motor complications. Guidelines for the diagnosis and management of 
patients with PD have been published from the National Institute for Health and 
Clinical Excellence (NICE) in the UK [2]. Parkinson disease can be diagnosed with 
Magnetic resonance imaging (MRI). Apart from good clinical diagnosis the imaging 
also helps in either endorsing the diagnosis or ruling out other possible differential 
possibilities. MRI can take a long time and it needs pre-scan screening of patients 
who cannot undergo this exams as there are certain contraindications which are 
beyond the scope of this chapter.
Parkinson’s Disease and Beyond - A Neurocognitive Approach
2
2. Neuroimaging in Parkinson’s disease
Over the past decades, neuroimaging studies which include structural, func-
tional and molecular modalities—have provided priceless understandings about the 
Parkinson disease (PD) [3]. Although PD is very complex, no neuroimaging modali-
ties are specifically recommended for routine use in clinical practice. However, 
conventional MRI and dopamine transporter imaging are used as adjuvant appa-
ratuses in the differential diagnosis between PD and other causes of Parkinsonism. 
Single-photon emission CT and PET are equally effective at differentiating between 
degenerative and nondegenerative causes of parkinsonism; MRI and PET can dif-
ferentiate between PD and atypical parkinsonism, but need sophisticated enhance-
ment methods [4]. Dopaminergic and serotonergic PET can be used to monitor PD 
progression, motor and nonmotor symptoms, and complications, whereas choliner-
gic PET is currently the most sensitive approach for assessing PD dementia. PET and 
other neuroimaging techniques should have a primary role in the development of 
protocols for new clinical trials, particularly those investigating cell therapy. Hybrid 
PET-MRI technology could offer a revolution in PD imaging [5].
The development of imaging which targets specific sites in the brain represents 
a significant advance in neurodegenerative diseases and Parkinson’s disease. The 
major roles of imaging include: (1) the use of neuroimaging in order to improve 
the accuracy, timeliness, and reliability of diagnosis; (2) objective monitoring of 
the progression of disease; (3) the evaluation of s “disease-modifying” treatments 
designed to retard the progression of disease by interfering with pathways thought 
implicated in the ongoing neuronal loss or replace dopamine-producing cells; 
(4) planning and evaluation of deep brain stimulation technique in candidates of 
surgery [6].
2.1 Radiological anatomy
In Parkinson disease, the main part involved is extrapyramidal system. The 
substantia nigra is the main brainstem nucleus and other one is the nucleus. The 
substantia nigra is seen in axial slices at both superior and inferior colliculi and red 
nuclei within an axial slice at the superior colliculi (see Figure 1). These nuclei are 
situated in the anterior midbrain and mark the transition point of the tegmentum 
and cerebral peduncles.
Substantia nigra consists of a compact part (dark, containing melanin) called 
pars compacta and a reticular part (reddish, containing iron) known as pars reticu-
lata. Most of its axons are projected diffusely to other brain areas and not arranged 
into tracts. Numerous axonal tracts terminate in the substantia nigra: from caudate 
nucleus (striatonigral fibers) from anterior cerebral cortex (corticonigral fibers) 
and from putamen from precentral cortex.
High resolution T2*/SWI weighted MRI is able to recognize the substantia 
nigra and red nuclei. They appear as hypointense on T2W, proton density and SWI 
sequences.
2.2 Protocol in neuroimaging
Magnetic resonance imaging (MRI) has proven to be the mainstay imaging 
technique in making the differential diagnosis between atypical Parkinsonism and 
Parkinson’s disease.
Conventional T1- and T2-weighted MRI sequences are not very helpful in 
diagnosing idiopathic Parkinson’s disease because nigral structures appear normal 
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in these routine sequences. Standard MRI sequences are very helpful in excluding 
secondary causes of Parkinsonism like structural basal ganglia lesions like granulo-
mas, calcification, vascular lesions, Wilsons disease/ephedrine poisoning.
With the advent of newer techniques-such as neuromelanin-sensitive MRI,  
T2/T2* relaxometry (quantification of iron overload), proton spectroscopy, dif-
fusion-weighted imaging (DWI), diffusion tensor imaging (DTI), magnetization 
transfer imaging, susceptibility-weighted imaging, perfusion-weighted imaging, 
and functional MRI—the role of MRI has evolved as has its role in the differential 
diagnosis between Parkinson’s disease and atypical parkinsonism.
Conventional MRI scans with T1-weighted, T2-weighted, weighted, fluid-
attenuated inversion recovery sequences and proton density-are usually normal 
in Parkinson’s disease. In Parkinson’s disease in axial T2-weighted sequences and 
susceptibility-weighted sequences significant thinning of the substantia nigra pars 
compacta diffuse cortical atrophy is noted however this imaging feature has shown 
high specificity, but low sensitivity and is found only in advanced stages of the 
disease [7].
2.3 Role of diffusion in Parkinson’s disease
In patients of Parkinson’s disease changes in water diffusion can be found in 
other regions of the brain even in its early stages, even when there is no significant 
cortical atrophy. It has been shown in studies that the fractional anisotropy is seen 
to be lower in the motor, premotor, and supplemental motor cortices of patients 
with Parkinson’s disease than that of control patients, likely due to degeneration in 
the corticostriatal and thalamocortical projections in the former [8].
Susceptibility-weighted imaging (SWI) uses the differences in magnetic 
susceptibility of tissues. By applying a gradient-recalled echo (GRE) sequence, a 
SW image combines a phase image with a magnitude image under high-intensity 
magnetic field such as 3 T and 7 T. In healthy individuals, in posterior one third of 
Figure 1. 
MRI anatomy of deep brain stem nuclei.
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substantia nigra a linear or comma shaped high signal intensity called Nigrosome-1 
is located it shows a distinct likeness to the split tail of sparrow in patients with 
Parkinson’s disease, the high SWI signal in nigrosome-1 is lost and the normal ‘swal-
low tail sign’ cannot be seen.
Advanced MRI sequences in high field magnets have opened the possibility 
of in vivo visualization of substantia nigra (SN) and has been able to investigate 
pathological changes specific to PD. It thus has enabled the development of high 
precision tools for disease diagnosis in early stages.
Early in the course of the disease and in preclinical stages there is diminution of 
dopaminergic neurons in the substantia nigra (SN) pars compacta (SNpc) and nor-
adrenergic neurons in the locus coeruleus (LC), which is characteristic of PD [9].
Depigmentation of the SN and LC is a discernible pathological feature of PD, 
which results due to the loss of a melanin pigment called neuromelanin.
A Japanese group in 2006 first described the use of specific MRI sequence that 
allowed the visualization of neuromelanin to the study of PD patients. Authors first 
described a high signal on specific T1-weighted images which is related to para-
magnetic properties of melanin pigment and has allowed for the first time in vivo 
of pathologic characteristics of PD. Neuromelanin (NM)-sensitive MR imaging is a 
T1-weighted fast spin-echo (FSE) sequence performed on 3.0 Tesla. NM-sensitive 
sequences have been successful in depicting neuromelanin signals through the 
use of high signal-to-noise ratio (using 3.0 T magnetic fields), the prolonged T1 
relaxation time of the brain and an indirect magnetization transfer effect [10].
Quantitative measurement of volumes of various regions of the brain are done 
by the use of advanced MR software. Voxel-based morphometry can be applied to 
volumetric MRI to see significant brain volume reduction in patients of Parkinson’s 
disease at voxel level. Patients with Parkinson’s disease studied with voxel-based 
morphometry, significant hippocampal, thalamic, and anterior cingulate atrophy 
can be detected of the brain [11].
MR spectroscopy has proven to be helpful in determining the levels of different 
metabolites in the brain parenchyma. Spectroscopy done in the affected region of brain 
shows a decreased N-acetyl aspartate to creatine (NAA/Cr) ratio. Evaluation of the 
pons, midbrain and putamen can be done for differentiating the various subtypes [12].
Magnetization transfer imaging: Different studies in literature have shown that 
magnetization transfer (MT) ratios are decreased in the affected areas of the brain. 
Therefore measurement of MT ratios in the substantia nigra, putamen and brain-
stem can be very helpful not in the diagnosis of PD but also to differentiate one 
from the other subtypes [13].
2.4 Role of NICE guidelines in Diagnosis of Parkinson’s disease
Parkinson’s disease is one of the most common neurodegenerative diseases, it 
was first described by James Parkinson in 1817, and the disease occurs due to nigral 
degeneration and striatal dopamine deficiency. Parkinson’s disease is clinically, 
characterized by motor symptoms such as stiffness, bradykinesia, resting tremor, 
and postural instability.
Symptoms PD do not appear until approximately 50% of the nigral dopamine (DA) 
neurons are lost. Expert clinical opinion is the gold-standard diagnostic technique in 
PD. In clinicopathological studies the sensitivity for establishing a clinical diagnosis of 
PD by a movement disorder specialist is reported to be as high as 91.1% in [14].
According to NICE guidelines for diagnosis of Parkinson’s disease:
1.2.1 Suspect Parkinson’s disease in people presenting with tremor, stiffness, 
slowness, balance problems and/or gait disorders [2006].
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1.2.2 If Parkinson’s disease is suspected, refer people quickly and untreated to 
a specialist with expertise in the differential diagnosis of this condition [2006, 
amended 2017].
2.4.1 Clinical and post-mortem diagnosis
1.2.3 Diagnose Parkinson’s disease clinically, based on the UK Parkinson’s 
Disease Society Brain Bank Clinical Diagnostic Criteria. [2006].
1.2.4 Encourage healthcare professionals to discuss with people with Parkinson’s 
disease the possibility of donating tissue to a brain bank for diagnostic confirmation 
and research. [2006].
2.4.2 Review of diagnosis
1.2.5 Review the diagnosis of Parkinson’s disease regularly, and reconsider it 
if atypical clinical features develop. (People diagnosed with Parkinson’s disease 
should be seen at regular intervals of 6–12 months to review their diagnosis.) 
[2006] Single photon emission computed tomography.
1.2.6 Consider 123I-FP-CIT single photon emission computed tomography 
(SPECT) for people with tremor if essential tremor cannot be clinically differenti-
ated from Parkinsonism [2006, amended 2017].
1.2.7 123I-FP-CIT SPECT should be available to specialists with expertise in its use 
and interpretation. [2006].
2.4.3 Positron emission tomography
1.2.8 Do not use positron emission tomography (PET) in the differential diag-
nosis of parkinsonian syndromes, except in the context of clinical trials [2006, 
amended 2017].
2.4.4 Structural MRI
1.2.9 Do not use structural MRI to diagnose Parkinson’s disease [2006, amended 
2017].
1.2.10 Structural MRI may be considered in the differential diagnosis of other 
parkinsonian syndromes [2006].
2.4.5 Magnetic resonance volumetry
1.2.11. Do not use magnetic resonance volumetry in the differential diagnosis 
of parkinsonian syndromes, except in the context of clinical trials [2006, amended 
2017].
2.4.6 Magnetic resonance spectroscopy
1.2.12. Do not use magnetic resonance spectroscopy in the differential diagnosis 
of parkinsonian syndromes [2006, amended 2017].
2.4.7 Acute levodopa and apomorphine challenge tests
1.2.13. Do not use acute levodopa and apomorphine challenge tests in the dif-
ferential diagnosis of parkinsonian syndromes [2006, amended 2017].
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2.4.8 Objective smell testing
1.2.14. Do not use objective smell testing in the differential diagnosis of parkin-
sonian syndromes, except in the context of clinical trials [2006, amended 2017].
2.5 Emerging role of neuroimaging
Structural and functional neuroimaging has become a valuable tool both in 
neuroscience research and in clinical settings. Different clinical and research 
applications of functional neuroimaging to Parkinson’s disease (PD) have advanced 
over the past decade.
2.5.1 Hybrid imaging
Hybrid PET/MRI has made it possible to obtain structural (MRI) and 
functional (PET) information simultaneously. The advantage of PET/MRI as a 
single-investigation for the comprehensive evaluation of neurodegenerative dis-
orders like PD is foreseeable. The role of PET/MRI, utilizing the F-18 florbetaben 
labeled stilbene derivative, a radiopharmaceutical that is developed to visualize 
beta-amyloid plaques in the brain in diagnosing patent’s with Alzheimer’s disease 
(AD) and is helpful in differentiating it from with Lewy body dementia (LBD) of 
Parkinson’s disease has been reported [15].
2.5.2 Functional imaging-SPECT and PET
In PD the imaging pattern of striatal involvement for all tracers shows an asym-
metric striatal decrease, which appears marked in side contralateral to the clinically 
affected side with a rostro-caudal gradient of uptake in this the posterior putamen is 
maximally affected [16].
2.5.3 Perfusion and metabolism imaging
Resting-state measurement of regional glucose utilization in the brain can be cal-
culated by using F-18 Fluorodeoxyglucose (FDG) PET. The pattern that is specific 
for PD is known as ‘Parkinson’s disease related pattern’ (PDRP), in which there is 
characteristic pallidothalamic and pontine hypermetabolism with hypometabolism 
seen in the prefrontal and parieto-occipital cortices. This pattern results from the 
underlying dopaminergic deficit in PD [17].
In patients with medically refractory tremors deep brain stimulation (DBS) of 
the motor thalamus and, the ventral intermedius nucleus (VIM), was first used in 
1986 [18]. In Parkinson’s disease, DBS of the internal globus pallidus (GPi) and the 
subthalamic nucleus (STN) were found to be safe and effective.
At present subthalamic nucleus (STN) is the main target nucleus for DBS in 
PD. Symptoms like rigidity, tremor akinesia and postural instability, that usually 
respond well to levodopa can be effectively treated by subthalamic nucleus (STN) 
DBS. Studies have shown that best outcome might be achieved by stimulation of 
the dorsolateral motor part of the STN. DBS should usually be performed bilater-
ally to relieve motor symptoms on both sides that allows for optimal reduction of 
medication.
In our institution we had diagnosed cases of Parkinson’s disease who underwent 
deep brain stimulation and they responded very well and there was significant 
reduction in motor symptoms of the patients.
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3. Insight in brain activation studies for motor functions
This is an overview of brain activation studies which describes findings that help in 
our understanding of the pathophysiology of motor, cognitive, and behavioral symp-
toms seen in Parkinson’s disease PD and the underlying neuronal changes. Activation 
studies of PD patients have been utilized to see the basal-ganglia-thalamocortical 
circuit function. Several types of motor tasks have been used in conjunction with 
different neuroimaging techniques to study the motor circuit in PD.
Most common tests included the repetitive tasks, involving either of these two, 
one was repeated thumb to other finger opposition movements second was manipu-
lation of a joystick in different directions. When normal subjects did repetitive right-
hand joystick movements in different directions while they underwent [15O]H2O 
PET, an increase in regional cerebral blood flow (rCBF) was noted in the contralat-
eral primary sensorimotor cortex and lentiform nucleus. Activation was also noted 
in the bilateral anterior cingulate gyrus, supplementary motor area (SMA), lateral 
premotor cortex, and dorsolateral prefrontal cortex. Opposite to that, PD patients 
showed a more complex activation pattern, which showed impaired rCBF changes 
in the lentiform nucleus, anterior cingulate gyrus, SMA, and dorsolateral prefrontal 
cortex. However normal activation was seen at the level of sensorimotor cortex, 
lateral, and parietal premotor cortex when compared with healthy controls [19].
The pattern of activation in PD varies significantly depending upon the stage 
of the disease, use of medication, and the type of motor task. In 1997 Samuel et al. 
hypothesized that nigrostriatal dopaminergic degeneration leads to hypoactiva-
tion of a mesial premotor system (SMA, anterior cingulate gyrus, and dorsolateral 
prefrontal cortex), frequently involved in self-paced movements.
The activation of the SMA was markedly improved when akinesia was reversed 
with apomorphine [19], rCBF was measured in PD patients at rest and when they 
performed joystick movements with the right hand in one of four freely chosen 
directions. All such patients were studied before and after treatment, in off state, 
and when “on” with apomorphine. It was seen that under resting conditions 
apomorphine had no effect on CBF, while significant activation of the SMA was 
observed while using the joystick with apomorphine.
The same group was also able to demonstrate that activation of the SMA signifi-
cantly improved when akinesia was reversed with apomorphine [19]. In particular, 
rCBF was measured in PD patients at rest and when performing paced joystick 
movements with the right hand in one of four freely chosen directions. All patients 
were studied before treatment, in an off state, and when “on” with apomorphine. 
Under resting conditions apomorphine had no effect on CBF, while significant acti-
vation of the SMA was observed while using the joystick with apomorphine [20].
Studies in the past few years have suggested that chronic electrical stimulation 
of the primary motor cortex (MCS) may alleviate motor symptoms of PD. This 
new approach can be viewed as another alternative approach for PD patients who 
are not ideal candidates for DBS of these subthalamic nuclei (STN). A study was 
conducted by Strafella et al. to understand the cortical and subcortical effects of 
MCS. Interestingly, they found that MCS at 50 and 130 Hz did not produce signifi-
cant changes in joystick motor performance or rCBF at cortical or subcortical levels. 
Therefore they concluded that while MCS was although a simpler and safer surgical 
procedure than DBS of the STN, it was not able to modify the pattern of movement 
related rCBF activation in PD patients [21, 22].
In conclusion, brain activation studies have been able to show the pathophysiol-
ogy of PD and the neurobiological foundation of its motor, cognitive, and behav-
ioral manifestations.
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4.  An overview of the current clinical evidence for morphological 
changes in the brain associated with symptoms (i.e. motor symptoms) 
and potential associated neural mechanisms
Parkinson’s disease (PD) is characteristically shown to have motor symptoms 
including resting tremor, rigidity, and bradykinesia but cognitive and behavioral 
problems in PD are more common and they have a direct effect on the quality of life.
The estimated prevalence of dementia in patients with PD ranges between 24 
and 31% has conservatively been estimated to range between 24 and 31%. Cognitive 
function in PD patients with dementia (PDD) is significantly different than that of 
the cortical dementia of Alzheimer’s disease (AD). Patients with PDD often exhibit 
difficulties with executive functions, the retrieval aspects of memory, and visuo-
spatial skills [23].
Patients with PDD often show a typical pattern of cognitive decline which shows 
characteristically a subcortical dementia that can be differentiated from AD in 
which cortical areas are affected early in the disease process and often include clear 
aphasia, apraxia, or agnosia. Dementia in PD is gradual in onset, and it is typically 
exhibited years after the onset of motor symptoms.
There is a difference between the pathophysiology of cognitive symptoms in 
PD and the pathophysiology of motor symptoms as well. Various factors have been 
implicated in the mechanism of disease process these, include dopamine depletion 
in the striatum and, to a lesser degree, in the prefrontal cortex. Due to disrup-
tion of dopamine levels at either site may there is resultant frontal-like deficits 
either directly or via downstream effects in striatal-pallidal-thalamocortical loops 
(CSPTC) [24].
Evidence has shown widespread cortical cholinergic dysfunction to be factor 
of cognitive decline in PD. Adrenergic and serotonergic deficits have also been 
described in PD but they have been associated with behavioral rather than cogni-
tive function. Regional cortical Lewy body formation, have also been implicated in 
cognitive decline in PD.
Antiparkinsonian therapy either surgical or medical has shown heterogeneous 
effects on cognitive functioning. Neuroimaging and behavioral studies in PD patients 
as well as experimental models have associated this heterogeneity to (i) task-specific 
differences in regional activation responses, (ii) differences in the location/degree of 
dopaminergic denervation which in turn depends on the stage of disease progression, 
(iii) baseline genetic features such as the COMT genotype, and (iv) on individual 
treatment status [25].
In short, neuroimaging studies have contributed significantly to the current 
understanding of cognitive functioning in PD, therefore because of the high vari-
ability seen in the time course of cognitive decline with advancing disease, and in 
cognitive response to antiparkinsonian treatment, further research and work are 
warranted.
5. Conclusion
PD is now a common neurodegenerative disease. A combination of genetic 
and environmental factors are likely cause leading to cell dysfunction and then 
death. The diagnosis is essentially clinical, and there should be a high index of 
suspicion to exclude other causes of Parkinsonism. A large number of investigation 
tools together with surgical interventions are now available to treat early and late 
complications of PD. Increasing consideration is being given to the diagnosis and 
treatment in PD.
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